{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:35Z","timestamp":1789469135020,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07123-9","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:35:37Z","timestamp":1781206537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute myeloid leukemia post cytotoxic therapy following medulloblastoma in a child successfully treated with a single cycle of CPX-351 followed by stem cell transplantation \u2013 a case report"],"prefix":"10.1007","volume":"105","author":[{"given":"Barbara","family":"Filar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Bednarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Czoga\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Garus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szymon","family":"Skocze\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Go\u017adzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Czoga\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"Supplement1","key":"7123_CR1","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1182\/blood-2019-131911","volume":"134","author":"K Waack","year":"2019","unstructured":"Waack K, R\u00f6llecke K, Rasche M, Walter C, Creutzig U, Reinhardt D (2019) Treatment-Related Acute Myeloid Leukemia in Children. Blood 134(Supplement1):1322. https:\/\/doi.org\/10.1182\/blood-2019-131911","journal-title":"Blood"},{"issue":"4","key":"7123_CR2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1177\/0394632016670667","volume":"29","author":"A Tragiannidis","year":"2016","unstructured":"Tragiannidis A, Gombakis N, Papageorgiou M, Hatzipantelis E, Papageorgiou T, Hatzistilianou M (2016) Treatment-related myelodysplastic syndrome (t-MDS)\/acute myeloid leukemia (AML) in children with cancer: A single-center experience. Int J Immunopathol Pharmacol 29(4):729\u2013730. https:\/\/doi.org\/10.1177\/0394632016670667","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"7","key":"7123_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36(7):1703\u20131719","journal-title":"Leukemia"},{"key":"7123_CR4","doi-asserted-by":"publisher","unstructured":"Czoga\u0142a M, Czoga\u0142a W, Pawi\u0144ska-W\u0105sikowska K et al (2023) Cancers (Basel) 15(3):734 Published 2023 Jan 25. https:\/\/doi.org\/10.3390\/cancers15030734. Pediatric Acute Myeloid Leukemia Post Cytotoxic Therapy-Retrospective Analysis of the Patients Treated in Poland from 2005 to 2022","DOI":"10.3390\/cancers15030734"},{"key":"7123_CR5","unstructured":"AML-BFM Study Group (2023) Treatment recommendations AML-BFM 2023. Version 12\/2023. AML-BFM Study Group, Berlin"},{"key":"7123_CR6","doi-asserted-by":"publisher","first-page":"e1414","DOI":"10.1634\/theoncologist.2019-0785","volume":"25","author":"K Tzogani","year":"2020","unstructured":"Tzogani K, Penttil\u00e4 K, Lapvetel\u00e4inen T, Hemmings R, Koenig J, Freire J et al (2020) EMA review of daunorubicin and cytarabine encapsulated in liposomes (Vyxeos, CPX-351) for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. Oncologist 25:e1414\u2013e1420","journal-title":"Oncologist"},{"key":"7123_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.23736\/S0026-4806.20.07017-2","volume":"111","author":"A Cafaro","year":"2020","unstructured":"Cafaro A, Giannini MB, Silimbani P, Cangini D, Masini C, Di Ror\u00e0 AGL et al (2020) CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia. Minerva Med 111:455\u2013466","journal-title":"Minerva Med"},{"key":"7123_CR8","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","volume":"8","author":"JE Lancet","year":"2021","unstructured":"Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK et al (2021) CPX-351 versus 7\u2009+\u20093 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 8:e481\u2013e491","journal-title":"Lancet Haematol"},{"key":"7123_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1182\/bloodadvances.2021006139","volume":"6","author":"Y Hu","year":"2022","unstructured":"Hu Y, Caldwell KJ, Onciu M, Federico SM, Salek M, Lewis S et al (2022) CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies. Blood Adv 6:521\u2013527","journal-title":"Blood Adv"},{"key":"7123_CR10","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1200\/JCO.19.03306","volume":"38","author":"TM Cooper","year":"2020","unstructured":"Cooper TM, Absalon MJ, Alonzo TA, Gerbing RB, Leger KJ, Hirsch BA et al (2020) Phase I\/II study of CPX-351 followed by fludarabine, cytarabine, and granulocyte-colony stimulating factor for children with relapsed acute myeloid leukemia: a report from the Children\u2019s Oncology Group. J Clin Oncol 38:2170\u20132177","journal-title":"J Clin Oncol"},{"key":"7123_CR11","unstructured":"Rheingold SR, Neugut AI, Meadows AT et al (2003) Therapy-Related Secondary Cancers. In: Kufe DW, Pollock RE, Weichselbaum RR (eds) Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK13999\/"},{"issue":"12","key":"7123_CR12","doi-asserted-by":"publisher","first-page":"e27410","DOI":"10.1002\/pbc.27410","volume":"65","author":"CA Brown","year":"2018","unstructured":"Brown CA, Youlden DR, Aitken JF, Moore AS (2018) Therapy-related acute myeloid leukemia following treatment for cancer in childhood: a population-based registry study. Pediatr Blood Cancer 65(12):e27410","journal-title":"Pediatr Blood Cancer"},{"issue":"15","key":"7123_CR13","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1182\/blood.2022018108","volume":"151","author":"J Othman","year":"2023","unstructured":"Othman J, Meggendorfer M, Tiacci E et al (2023) Overlapping features of therapy-related and de novo NPM1-mutated AML. Blood 151(15):1846\u20131857. https:\/\/doi.org\/10.1182\/blood.2022018108","journal-title":"Blood"},{"issue":"4","key":"7123_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.5045\/br.2016.51.4.242","volume":"51","author":"HW Cho","year":"2016","unstructured":"Cho HW, Choi YB, Yi ES, Lee JW, Sung KW, Koo HH et al (2016) Therapy-related myeloid neoplasms in children and adolescents. Blood Res 51(4):242\u2013247","journal-title":"Blood Res"},{"key":"7123_CR15","doi-asserted-by":"publisher","first-page":"1364199","DOI":"10.3389\/fonc.2024.1364199","volume":"14","author":"LS Mak","year":"2024","unstructured":"Mak LS, Li X, Chan WYK, Leung AWK, Cheuk DKL, Yuen LYP, So JCC, Ha SY, Liu APY (2024) Case report: Therapy-related myeloid neoplasms in three pediatric cases with medulloblastoma. Front Oncol 14:1364199. https:\/\/doi.org\/10.3389\/fonc.2024.1364199","journal-title":"Front Oncol"},{"issue":"10","key":"7123_CR16","doi-asserted-by":"publisher","first-page":"6729","DOI":"10.1097\/MS9.0000000000003650","volume":"87","author":"Z Karaki","year":"2025","unstructured":"Karaki Z, Kotaich J, Chemaly C, Mourad M, Dhayni R (2025) Therapy-related acute myeloid leukemia following aggressive treatment for pediatric medulloblastoma: a case report of a 13-year-old and review of literature. Ann Med Surg (Lond) 87(10):6729\u20136734 Published 2025 Aug 5. https:\/\/doi.org\/10.1097\/MS9.0000000000003650","journal-title":"Ann Med Surg (Lond)"},{"key":"7123_CR17","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","volume":"25","author":"AC Krauss","year":"2019","unstructured":"Krauss AC, Gao X, Li L, Manning ML, Patel P, Fu W et al (2019) FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia. Clin Cancer Res 25:2685\u20132690","journal-title":"Clin Cancer Res"},{"key":"7123_CR18","volume-title":"An overview of Vyxeos liposomal and why it is authorised in the EU [Internet]","author":"European Medicines Agency","year":"2019","unstructured":"European Medicines Agency (2019) Vyxeos liposomal (daunorubicin \/ cytarabine). An overview of Vyxeos liposomal and why it is authorised in the EU [Internet]. EMA, London. [cited 2025 Apr 3]."},{"issue":"Supplement 1","key":"7123_CR19","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1182\/blood-2024-205666","volume":"144","author":"JA Pollard","year":"2024","unstructured":"Pollard JA, Alonzo TA, Gerbing R, Kutny MA, Hirsch B, Raca G, Leger K, Wilkes JJ, Wadhwa A, Graff Z, Pabari R, Kahwash S, Chisholm KM, Chewning J, Horan JT, Aplenc R, Tarlock K, Menig S, Militano O, Ky B, Hudson CA, Eidenschink Brodersen L, Loken MR, Meshinchi S, Kolb A, Cooper TM (2024) A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO - a Report from the Children\u2019s Oncology Group. Blood 144(Supplement 1):967. https:\/\/doi.org\/10.1182\/blood-2024-205666","journal-title":"Blood"},{"key":"7123_CR20","doi-asserted-by":"publisher","unstructured":"Bender JD, Pommert L, Backus LR et al (2026) Pediatr Blood Cancer e70268. https:\/\/doi.org\/10.1002\/1545-5017.70268. CPX-351 in High-Risk Relapsed Pediatric Acute Leukemia: Real-World Phase 1 Data Establishing the FDA-Approved Dose","DOI":"10.1002\/1545-5017.70268"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07123-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07123-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07123-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:42:59Z","timestamp":1789465379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07123-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7123"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07123-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8330941\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed for publication was obtained from the patient\u2019s parents.","order":3,"name":"Ethics","label":"Patient consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"379"}}